Table 4. Covariates of CVD risk score as predictors for CKD events adjusted for CKD risk group.
| Risk group or covariate | Adjusted only for CKD risk group | Fully adjusted model | ||
|---|---|---|---|---|
| IRR (95% CI) | p-Value | IRR (95% CI) | p-Value | |
| CKD ≤1% | 1.00 | 1.0 | ||
| CKD >1%–5% | 4.92 (3.98, 6.09) | <0.001 | 4.49 (3.63, 5.57) | <0.001 |
| CKD >5% | 23.56 (19.30, 28.77) | <0.001 | 20.53 (16.77, 25.14) | <0.001 |
| Family history of CVD (yes) | 0.95 (0.80, 1.14) | 0.617 | ||
| Current smoker | 0.91 (0.80, 1.03) | 0.121 | ||
| Ex-smoker | 1.01 (0.88, 1.17) | 0.861 | ||
| Ln total cholesterol | 1.48 (1.20, 1.83) | <0.001 | 1.49 (1.20, 1.84) | <0.001 |
| Ln HDL cholesterol | 0.89 (0.77, 1.03) | 0.121 | ||
| Ln base 2 CD4 count | 0.90 (0.86, 0.95) | <0.001 | 0.87 (0.83, 0.91) | <0.001 |
| Receiving abacavir | 0.93 (0.81, 1.06) | 0.287 | ||
| Cumulative PI use | 1.11 (1.06, 1.15) | <0.001 | 1.04 (0.99, 1.10) | 0.149 |
| Cumulative N(t)RTI use | 1.05 (1.03, 1.08) | <0.001 | 1.04 (1.02, 1.07) | 0.002 |
CKD, chronic kidney disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; IRR, incidence rate ratio; N(t)RTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor.